Literature DB >> 25510948

Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders.

Laura Koenders1, Marise W J Machielsen1, F J van der Meer1, Angelique C M van Gasselt1, Carin J Meijer1, Wim van den Brink1, Maarten W J Koeter1, Matthan W A Caan2, Janna Cousijn1, Anouk den Braber3, Dennis van 't Ent3, Maaike M Rive1, Aart H Schene4, Elsmarieke van de Giessen2, Chaim Huyser5, Bart P de Kwaasteniet1, Dick J Veltman6, Lieuwe de Haan1.   

Abstract

BACKGROUND: Schizophrenia is highly comorbid with cannabis use disorders (CUDs), and this comorbidity is associated with an unfavourable course. Early onset or frequent cannabis use may influence brain structure. A key question is whether comorbid CUDs modulate brain morphology alterations associated with schizophrenia.
METHODS: We used surface-based analysis to measure the brain volume, cortical thickness and cortical surface area of a priori-defined brain regions (hippocampus, amygdala, thalamus, caudate, putamen, orbitofrontal cortex, anterior cingulate cortex, insula, parahippocampus and fusiform gyrus) in male patients with schizophrenia or related disorders with and without comorbid CUDs and matched healthy controls. Associations between age at onset and frequency of cannabis use with regional grey matter volume were explored.
RESULTS: We included 113 patients with (CUD, n = 80) and without (NCUD, n = 33) CUDs and 84 controls in our study. As expected, patients with schizophrenia (with or without a CUD) had smaller volumes of most brain regions (amygdala, putamen, insula, parahippocampus and fusiform gyrus) than healthy controls, and differences in cortical volume were mainly driven by cortical thinning. Compared with the NCUD group, the CUD group had a larger volume of the putamen, possibly driven by polysubstance use. No associations between age at onset and frequency of use with regional grey matter volumes were found. LIMITATIONS: We were unable to correct for possible confounding effects of smoking or antipsychotic medication.
CONCLUSION: Patients with psychotic disorders and comorbid CUDs have larger putamen volumes than those without CUDs. Future studies should elaborate whether a large putamen represents a risk factor for the development of CUDs or whether (poly)substance use causes changes in putamen volume.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25510948      PMCID: PMC4409437          DOI: 10.1503/jpn.140081

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  58 in total

1.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

2.  Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders.

Authors:  Sanjiv Kumra; Paul Robinson; Rabindra Tambyraja; Daniel Jensen; Caroline Schimunek; Alaa Houri; Tiffany Reis; Kelvin Lim
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-12-14       Impact factor: 8.829

Review 3.  The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature.

Authors:  Valentina Lorenzetti; Nadia Solowij; Alex Fornito; Dan Ian Lubman; Murat Yucel
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  Regional specificity of sex effects on subcortical volumes across the lifespan in healthy aging.

Authors:  Wenjing Li; Marie-José van Tol; Meng Li; Wen Miao; Yonghong Jiao; Hans-Jochen Heinze; Bernhard Bogerts; Huiguang He; Martin Walter
Journal:  Hum Brain Mapp       Date:  2012-09-21       Impact factor: 5.038

5.  Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS).

Authors:  A James; M Hough; S James; L Winmill; L Burge; S Nijhawan; P M Matthews; M Zarei
Journal:  Schizophr Res       Date:  2011-03-08       Impact factor: 4.939

Review 6.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

7.  Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects.

Authors:  Krista Lisdahl Medina; Tim McQueeny; Bonnie J Nagel; Karen L Hanson; Tony T Yang; Susan F Tapert
Journal:  Addict Biol       Date:  2009-07-24       Impact factor: 4.280

Review 8.  Cannabis use and the mental health of young people.

Authors:  Wayne D Hall
Journal:  Aust N Z J Psychiatry       Date:  2006-02       Impact factor: 5.744

Review 9.  Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence.

Authors:  Berend Malchow; Alkomiet Hasan; Paolo Fusar-Poli; Andrea Schmitt; Peter Falkai; Thomas Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-21       Impact factor: 5.270

10.  Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use.

Authors:  Ana González-Pinto; Susana Alberich; Sara Barbeito; Miguel Gutierrez; Patricia Vega; Berta Ibáñez; Mahmoud Karim Haidar; Eduard Vieta; Celso Arango
Journal:  Schizophr Bull       Date:  2009-11-13       Impact factor: 9.306

View more
  10 in total

1.  Impact of substance use disorder on gray matter volume in schizophrenia.

Authors:  Margaret Quinn; Maureen McHugo; Kristan Armstrong; Neil Woodward; Jennifer Blackford; Stephan Heckers
Journal:  Psychiatry Res Neuroimaging       Date:  2018-08-03       Impact factor: 2.376

Review 2.  Neuroimaging Studies in Patients With Mental Disorder and Co-occurring Substance Use Disorder: Summary of Findings.

Authors:  Kaloyan Rumenov Stoychev
Journal:  Front Psychiatry       Date:  2019-10-23       Impact factor: 4.157

3.  Multivariate Associations Among Behavioral, Clinical, and Multimodal Imaging Phenotypes in Patients With Psychosis.

Authors:  Dominik A Moser; Gaelle E Doucet; Won Hee Lee; Alexander Rasgon; Hannah Krinsky; Evan Leibu; Alex Ing; Gunter Schumann; Natalie Rasgon; Sophia Frangou
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

Review 4.  Cannabis and Psychosis: a Critical Overview of the Relationship.

Authors:  Charles Ksir; Carl L Hart
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

5.  Systematic review of structural and functional neuroimaging studies of cannabis use in adolescence and emerging adulthood: evidence from 90 studies and 9441 participants.

Authors:  Sarah D Lichenstein; Nick Manco; Lora M Cope; Leslie Egbo; Kathleen A Garrison; Jillian Hardee; Ansel T Hillmer; Kristen Reeder; Elisa F Stern; Patrick Worhunsky; Sarah W Yip
Journal:  Neuropsychopharmacology       Date:  2021-11-27       Impact factor: 8.294

6.  A History of Psychosis in Bipolar Disorder is Associated With Gray Matter Volume Reduction.

Authors:  Carl Johan Ekman; Predrag Petrovic; Anette G M Johansson; Carl Sellgren; Martin Ingvar; Mikael Landén
Journal:  Schizophr Bull       Date:  2016-06-11       Impact factor: 9.306

7.  Testing associations between cannabis use and subcortical volumes in two large population-based samples.

Authors:  Nathan A Gillespie; Michael C Neale; Timothy C Bates; Lisa T Eyler; Christine Fennema-Notestine; Jasmin Vassileva; Michael J Lyons; Elizabeth C Prom-Wormley; Katie L McMahon; Paul M Thompson; Greig de Zubicaray; Ian B Hickie; John J McGrath; Lachlan T Strike; Miguel E Rentería; Matthew S Panizzon; Nicholas G Martin; Carol E Franz; William S Kremen; Margaret J Wright
Journal:  Addiction       Date:  2018-04-24       Impact factor: 6.526

8.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

9.  Structural MRI Differences between Patients with and without First Rank Symptoms: A Delusion?

Authors:  Henriette D Heering; Godefridus J C Koevoets; Laura Koenders; Marise W J Machielsen; Carin J Meijer; Manabu Kubota; Jessica de Nijs; Wiepke Cahn; Hilleke E Hulshoff Pol; Lieuwe de Haan; Rene S Kahn; Neeltje E M van Haren
Journal:  Front Psychiatry       Date:  2015-07-29       Impact factor: 4.157

10.  Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape.

Authors:  Musa Sami; James H Cole; Matthew J Kempton; Luciano Annibale; Debasis Das; Marlene Kelbrick; Savitha Eranti; Tracy Collier; Chidimma Onyejiaka; Aisling O'Neill; David J Lythgoe; Philip McGuire; Steve C R Williams; Sagnik Bhattacharyya
Journal:  Hum Brain Mapp       Date:  2020-07-20       Impact factor: 5.399

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.